This guidance updates 2021 GRADE (Grading of Recommendations Assessment, Development and Evaluation) recommendations regarding immediate allergic reactions following coronavirus disease 2019 (COVID-19) vaccines and addresses revaccinating individuals with first-dose allergic reactions and allergy testing to determine revaccination outcomes. Recent meta-analyses assessed the incidence of severe allergic reactions to initial COVID-19 vaccination, risk of mRNA-COVID-19 revaccination after an initial reaction, and diagnostic accuracy of COVID-19 vaccine and vaccine excipient testing in predicting reactions. GRADE methods informed rating the certainty of evidence and strength of recommendations. A modified Delphi panel consisting of experts in allergy, anaphylaxis, vaccinology, infectious diseases, emergency medicine, and primary care from Australia, Canada, Europe, Japan, South Africa, the United Kingdom, and the United States formed the recommendations. We recommend vaccination for persons without COVID-19 vaccine excipient allergy and revaccination after a prior immediate allergic reaction. We suggest against >15-minute postvaccination observation. We recommend against mRNA vaccine or excipient skin testing to predict outcomes. We suggest revaccination of persons with an immediate allergic reaction to the mRNA vaccine or excipients be performed by a person with vaccine allergy expertise in a properly equipped setting. We suggest against premedication, split-dosing, or special precautions because of a comorbid allergic history.

Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach / Greenhawt, M.; Dribin, T. E.; Abrams, E. M.; Shaker, M.; Chu, D. K.; Golden, D. B. K.; Akin, C.; Anagnostou, A.; Almuhizi, F.; Alqurashi, W.; Arkwright, P.; Baldwin, J. L.; Banerji, A.; Begin, P.; Ben-Shoshan, M.; Bernstein, J.; Bingemann, T. A.; Bindslev-Jensen, C.; Blumenthal, K.; Byrne, A.; Cahill, J.; Cameron, S.; Campbell, D.; Campbell, R.; Cavender, M.; Chan, E. S.; Chinthrajah, S.; Comberiati, P.; Eastman, J. J.; Ellis, A. K.; Fleischer, D. M.; Fox, A.; Frischmeyer-Guerrerio, P. A.; Gagnon, R.; Garvey, L. H.; Grayson, M. H.; Isabwe, G. A. C.; Hartog, N.; Hendron, D.; Horner, C. C.; Hourihane, J. O.; Iglesia, E.; Kan, M.; Kaplan, B.; Katelaris, C. H.; Kim, H.; Kelso, J. M.; Khan, D. A.; Lang, D.; Ledford, D.; Levin, M.; Lieberman, J. A.; Loh, R.; Mack, D. P.; Mazer, B.; Mody, K.; Mosnaim, G.; Munblit, D.; Mustafa, S. S.; Nanda, A.; Nathan, R.; Oppenheimer, J.; Otani, I. M.; Park, M.; Pawankar, R.; Perrett, K. P.; Peter, J.; Phillips, E. J.; Picard, M.; Pitlick, M.; Ramsey, A.; Rasmussen, T. H.; Rathkopf, M. M.; Reddy, H.; Robertson, K.; Rodriguez del Rio, P.; Sample, S.; Sheshadri, A.; Sheik, J.; Sindher, S. B.; Spergel, J. M.; Stone, C. A.; Stukus, D.; Tang, M. L. K.; Tracy, J. M.; Turner, P. J.; Vander Leek, T. K.; Wallace, D. V.; Wang, J.; Wasserman, S.; Weldon, D.; Wolfson, A. R.; Worm, M.; Yacoub, M. -R.. - In: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. - ISSN 0091-6749. - 152:2(2023), pp. 309-325. [10.1016/j.jaci.2023.05.019]

Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach

Yacoub M. -R.
Ultimo
2023-01-01

Abstract

This guidance updates 2021 GRADE (Grading of Recommendations Assessment, Development and Evaluation) recommendations regarding immediate allergic reactions following coronavirus disease 2019 (COVID-19) vaccines and addresses revaccinating individuals with first-dose allergic reactions and allergy testing to determine revaccination outcomes. Recent meta-analyses assessed the incidence of severe allergic reactions to initial COVID-19 vaccination, risk of mRNA-COVID-19 revaccination after an initial reaction, and diagnostic accuracy of COVID-19 vaccine and vaccine excipient testing in predicting reactions. GRADE methods informed rating the certainty of evidence and strength of recommendations. A modified Delphi panel consisting of experts in allergy, anaphylaxis, vaccinology, infectious diseases, emergency medicine, and primary care from Australia, Canada, Europe, Japan, South Africa, the United Kingdom, and the United States formed the recommendations. We recommend vaccination for persons without COVID-19 vaccine excipient allergy and revaccination after a prior immediate allergic reaction. We suggest against >15-minute postvaccination observation. We recommend against mRNA vaccine or excipient skin testing to predict outcomes. We suggest revaccination of persons with an immediate allergic reaction to the mRNA vaccine or excipients be performed by a person with vaccine allergy expertise in a properly equipped setting. We suggest against premedication, split-dosing, or special precautions because of a comorbid allergic history.
2023
allergic reactions
anaphylaxis
COVID-19
mRNA COVID-19 vaccine
polyethylene glycol
polysorbate 80
repeat allergic reactions
SARS-CoV-2
skin testing
vaccination
File in questo prodotto:
File Dimensione Formato  
PIIS0091674923007467.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Copyright dell'editore
Dimensione 2.19 MB
Formato Adobe PDF
2.19 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/165818
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 6
social impact